• Cellectis disclosed final Phase 1 results for lasme-cel in relapsed or refractory B-cell acute lymphoblastic leukemia, slated for presentation at EHA 2026.
• The data showed broad responses in a heavily pretreated group, supporting use as a bridge to stem cell transplant with manageable safety.
• The pivotal Phase 2 BALLI-01 study remains open for recruitment, with a first interim readout expected in Q4 2026.
• Separately, preliminary NATHALI-01 findings for eti-cel in relapsed or refractory B-cell non-Hodgkin lymphoma will be presented at EHA 2026.
• Early results indicated meaningful activity in a hard-to-treat population, with dosing optimization work aimed at improving expansion and response durability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110240PRIMZONEFULLFEED9734961) on June 11, 2026, and is solely responsible for the information contained therein.